After Pfizer and Moderna, it arrives AstraZeneca. The Italian Medicines Agency has authorized the anti-Covid vaccine developed in Oxford. The serum had already been authorized by EMA, the European body for medicines. For Italy, however, the authorization is not total. The preferential use of the vaccine on subjects under the age of 55 is recommended.
The vaccines from Pfizer (95% effective), Moderna (reaches 94.5%) and AstraZeneca differ in the technology used. The first two are based on the mRna messagger technologyor. In the vaccine there is synthetic ribonucleic acid with instructions for making the coronavirus proteins. The immune system learns to recognize and fight them.
AstraZeneca’s vaccine uses a instead viral vector chimpanzee based on a weakened version of a virus. It contains the genetic material of the spike protein of the Sars-Cov-2 virus which, after vaccination, the body learns to recognize.
AstraZeneca’s estimated efficacy for its vaccine is 70.3%. However, certain data on efficacy beyond the age of 55 are lacking due to the lack of experimentation (only 8% among the test persons). This is why the Italian company invites not to use it for older people. On the other hand, Europe has not set limits for individuals aged 18 and over. Germany has chosen not to use it for those over 65, in Italy it will be the Ministry of Health that will decide the indications for administration. The position may be reviewed in the light of new data provided by the pharmaceutical company.
The advantage of the AstraZeneca vaccine is the conservation method. For the Pfizer / BioNTech vaccine you need a temperature around -70 degrees, minus 20 for Moderna is needed, for the latest approved a normal refrigerator temperature is enough. All three licensed vaccines are given in two doses. For AstraZeneca the distance between the two must be 4-12 weeks, for Pfizer the days are 21, for Moderna 28.
The first doses of the vaccine are expected to arrive on Monday 8 February.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
